Despite significant advances in cryopreservation over the last decades, there is room for further progress. Some sectors require higher post-thaw recovery, others more efficient protocols, and others safer clinical use through reduced cryoprotective agent (CPA) concentrations. In many cases, a combination of these improvements is needed. CryoEmbla has the potential to address all of these.

The market is driven by the growing use of advanced biotechnologies such as cell-based therapies, biobanking and biopharmaceuticals. With continuous technological advancements and a stronger focus on quality and compliance, the cryopreservation market is expected to evolve and grow significantly in the coming years.